Article
Radiology, Nuclear Medicine & Medical Imaging
Lin Yan, Yu Lan, Jing Xiao, Lin Lin, Bo Jiang, Yukun Luo
Summary: This study evaluated the long-term efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population. The results showed that RFA was effective in treating PTMC with significant reduction in tumor volume, low incidence of complications, and no life-threatening events during the follow-up period.
EUROPEAN RADIOLOGY
(2021)
Article
Surgery
Lin Yan, Ying Liu, WenHui Li, YaLin Zhu, Jinling Wang, Mingbo Zhang, Jie Tang, Ying Che, Hui Wang, Shurong Wang, Yukun Luo
Summary: This study found that ultrasound-guided thermal ablation is an effective and safe treatment option for patients with solitary low-risk papillary thyroid microcarcinoma, based on a retrospective multicenter cohort with more than 5-year follow-up.
Article
Endocrinology & Metabolism
Althaf K. Majeed, Swayamjeet Satapathy, Sanjana Ballal, Chandrasekhar Bal
Summary: The study validates the use of Dynamic Risk Stratification (DRS) in pediatric differentiated thyroid cancers (DTCs). DRS accurately predicts long-term outcomes and can aid in personalized treatment and follow-up strategies for pediatric DTCs.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Oncology
Miriam Steinschneider, Jacob Pitaro, Shlomit Koren, Yuval Mizrakli, Carlos Benbassat, Limor Muallem Kalmovich
Summary: Although a portion of patients with differentiated thyroid cancer may progress to structural disease when exhibiting a biochemical incomplete response, the majority of patients present with an indolent disease course. Prediction of progression to structural disease can be facilitated by utilizing the American Thyroid Association's Initial Risk Stratification system and/or the AJCC/TNM staging system.
Article
Otorhinolaryngology
Ping Dong, Li Wang, Yuan Qu, Rui Huang, Lin Li
Summary: The study showed that low-dose radioiodine ablation was as effective as high dose in Chinese patients with differentiated thyroid cancer, with similar success rates between the two groups. This indicates that lower doses of radioiodine may be a suitable treatment option for DTC patients in China.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Article
Medicine, General & Internal
Aleksandra Kukulska, Jolanta Krajewska, Marzena Gawkowska, Ewa Paliczka-Cieslik, Daria Handkiewicz-Junak, Aleksandra Kropinska, Zbigniew Puch, Tomasz Olczyk, Jozef Roskosz, Barbara Jarzab
Summary: This study evaluated the long-term outcomes of differentiated thyroid cancer (DTC) patients treated with different radioiodine (RAI) activities. The results showed that 30 mCi of RAI activity had comparable efficacy to 60 mCi and 100 mCi in low-risk DTC, while 60 mCi of RAI activity seemed to be effective in intermediate-risk DTC.
ARCHIVES OF MEDICAL SCIENCE
(2022)
Letter
Medicine, General & Internal
Mark Tulchinsky
Summary: This article discusses the comparison of radioactive iodine ablation and observation in low-risk patients with differentiated thyroid cancer. The author states that the use of radioiodine ablation has disappeared from practice in the United States, rendering the article unnecessary.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Thomas J. Vogl, Maximilian Zitsch, Moritz Albrecht, Tommaso D'Angelo, Lajos Basten, Tatjana Gruber-Rouh, Nour-Eldin A. Nour-Eldin, Nagy N. N. Naguib
Summary: Microwave ablation (MWA) can achieve satisfactory overall survival (OS) and local tumor progression-free survival (PFS) in patients with colorectal cancer liver metastases (CRLM). The number of metastases and the location of the primary tumor are significant prognostic factors.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2022)
Article
Endocrinology & Metabolism
Jia-Rui Du, Wen-Hui Li, Cheng-Hai Quan, Hui Wang, Deng-Ke Teng
Summary: The long-term results of microwave ablation (MWA) for benign thyroid nodules (BTNs) were evaluated in this study, with a 48-month follow-up on 148 patients. The study concluded that MWA is an effective method for treating BTNs, showing satisfactory long-term efficacy.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Gastroenterology & Hepatology
Allon Kahn, Kevin Song, Lovekirat Dhaliwal, Shivani Thanawala, Catherine E. Hagen, Siddharth Agarwal, Nicholas M. Mcdonald, Joel T. Gabre, Gary W. Falk, Gregory G. Ginsberg, Herbert C. Wolfsen, Francisco C. Ramirez, Cadman L. Leggett, Kenneth K. Wang, Prasad G. Iyer
Summary: The aim of this study is to evaluate the incidence and predictors of long-term recurrence in patients with T1 esophageal adenocarcinoma treated with endoscopic eradication therapy (EET). The results show that 8.3% of patients experienced tumor recurrence after 5 years of successful EET. Complete eradication of intestinal metaplasia is associated with reduced recurrence.
GASTROINTESTINAL ENDOSCOPY
(2023)
Article
Endocrinology & Metabolism
Anwar Ali Jammah, Ibrahim Mohammed AlSadhan, Ebtihal Y. Alyusuf, Mubarak Alajmi, Abdullah Alhamoudi, Mohammed E. Al-Sofiani
Summary: This study retrospectively reviewed 20 years of experience in managing thyroid cancer and found that tumor size, lymphovascular invasion, and obesity are strong predictors of a worse response to therapy. ATA risk stratification is well correlated with patient long-term outcomes.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Takuya Hashimoto, Satoshi Yamamoto, Masaru Kimura, Masaya Sano, Osamu Sato, Juno Deguchi
Summary: This study retrospectively evaluated the long-term outcomes of femoral endarterectomy (FEA) in the treatment of intermittent claudication (IC) and chronic limb-threatening ischemia (CLTI). The results showed that FEA had durable efficacy and supported a strategy combining open and endovascular approaches.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Engineering, Environmental
Qi Long, Zhenpeng Zhang, Yuan Li, Yuxu Zhong, Hongyan Liu, Lei Chang, Ying Ying, Tao Zuo, Yong'an Wang, Ping Xu
Summary: This study used mice to examine the effects of different doses of soman over time, and phosphoproteomic analysis of the mouse brain was used for the first time to detect the underlying biological changes and persistent neurocognitive dysfunction caused by low dosage of soman.
JOURNAL OF HAZARDOUS MATERIALS
(2023)
Article
Endocrinology & Metabolism
Angeliki Chorti, Vangelis Bontinis, Georgios Tzikos, Alkis Bontinis, Aristeidis Ioannidis, Antonios Michalopoulos, Theodossis Papavramidis
Summary: This study comprehensively reviewed the efficacy and safety of thermal ablation modalities for benign thyroid nodules. The results showed no significant differences among different thermal ablation interventions in terms of volume reduction rate, symptomatic score, and cosmetic score. Conventional surgery, laser ablation, and microwave ablation were identified as the three interventions that were most likely to result in the largest volume reduction rate and improvement in symptomatic and cosmetic scores. Compared to conventional surgery, radiofrequency ablation, laser ablation, and microwave ablation were associated with lower risks for post-intervention vocal complications, transient laryngeal nerve injury, and hypothyroidism. Radiofrequency ablation also had a reduced risk of nodular regrowth compared to conventional surgery.
Article
Endocrinology & Metabolism
Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim
Summary: Comparison of long-term outcomes between intermediate-dose and high-dose RAI ablation therapy in patients with DTC revealed that intermediate-dose treatment is sufficient. LN ratio and post-RAI serum Tg levels are significant predictors of recurrence.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
(2021)
Review
Oncology
Akshat Malik, John C. Hardman, Yadsan Devabalan, Christopher Nutting, Shreerang Bhide, Kevin Harrington, Clare Schilling, Vinidh Paleri
Summary: A systematic review and meta-analysis was conducted to evaluate occult contralateral nodal metastases (OCM) in patients undergoing bilateral neck dissection for surgically treated oropharyngeal squamous cell carcinoma (OPSCC). The study found that OCM were seen in 9.8% of patients, with a higher rate in cN positive necks compared to cN0 necks. This highlights the importance of considering contralateral neck involvement in the surgical treatment of OPSCC.
Article
Oncology
Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin
Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Robert I. Haddad, Kevin Harrington, Makoto Tahara, Robert L. Ferris, Maura Gillison, Jerome Fayette, Amaury Daste, Piotr Koralewski, Bogdan Zurawski, Miren Taberna, Nabil F. Saba, Milena Mak, Andrzej Kawecki, Gustavo Girotto, Miguel Angel Alvarez Avitia, Caroline Even, Joaquin Gabriel Reinoso Toledo, Alexander Guminski, Urs Muller-Richter, Naomi Kiyota, Mustimbo Roberts, Tariq Aziz Khan, Karen Miller-Moslin, Li Wei, Athanassios Argiris
Summary: In patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), first-line nivolumab plus ipilimumab did not show a significant difference in overall survival compared to the standard treatment. However, there may be some advantages in certain populations, and it has a better safety profile.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Charles M. Rudin, Hardev S. Pandha, Matthew Zibelman, Wallace L. Akerley, Kevin J. Harrington, Daphne Day, Andrew G. Hill, Steven J. O'Day, Timothy D. Clay, Gavin M. Wright, Ross R. Jennens, David E. Gerber, Jonathan E. Rosenberg, Christy Ralph, David C. Campbell, Brendan D. Curti, Jaime R. Merchan, Yixin Ren, Emmett Schmidt, Lisa Guttman, Sumati Gupta
Summary: This study evaluated the efficacy and safety of V937 combined with pembrolizumab in patients with advanced solid tumors. The results showed that the combination therapy had a manageable safety profile, but did not achieve greater efficacy than pembrolizumab monotherapy in non-small cell lung cancer and urothelial cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Cara Owens, Alex Fitzhugh, Kevin Harrington, Vinidh Paleri, Bhupinder Sharma, Joshua Shur, Derfel ap Dafydd
Summary: This retrospective study assessed the clinical outcomes of patients with a primary malignancy who had incidentally detected thyroid cancer on their F-18-FDG PET-CT imaging. After a search of imaging records, patient demographics, oncological diagnosis, and stage were recorded. The results showed that the clinical outcomes of patients with an established primary malignancy are determined by their primary cancer and not by incidentally detected thyroid cancer, suggesting a potential 'watch-and-wait' approach for incidental thyroid nodules.
NUCLEAR MEDICINE COMMUNICATIONS
(2023)
Article
Oncology
Fabiana Gregucci, Sheila Spada, Mary Helen Barcellos-Hoff, Nina Bhardwaj, Charleen Chan Wah Hak, Alba Fiorentino, Chandan Guha, Monica L. Guzman, Kevin Harrington, Fernanda G. Herrera, Jamie Honeychurch, Theodore Hong, Lorea Iturri, Elisabeth Jaffee, Sana D. Karam, Simon R. V. Knott, Constantinos Koumenis, David Lyden, Ariel E. Marciscano, Alan Melcher, Michele Mondini, Anna Mondino, Zachary S. Morris, Sean Pitroda, Sergio A. Quezada, Laura Santambrogio, Stephen Shiao, John Stagg, Irma Telarovic, Robert Timmerman, Marie-Catherine Vozenin, Ralph Weichselbaum, James Welsh, Anna Wilkins, Chris Xu, Roberta Zappasodi, Weiping Zou, Alexandre Bobard, Sandra Demaria, Lorenzo Galluzzi, Eric Deutsch, Silvia C. Formenti
Summary: Focal radiation therapy has potential as a partner for immunotherapy, but there is a need for a better understanding of their interaction. The ImmunoRad conference provides a platform for experts to share knowledge and promote progress in the field. This article summarizes the key concepts and findings presented at the Sixth Annual ImmunoRad conference.
Article
Oncology
Kevin J. Harrington, Robert L. Ferris, Maura Gillison, Makoto Tahara, Athanasios Argiris, Jerome Fayette, Michael Schenker, Ase Bratland, John W. T. Walker, Peter Grell, Caroline Even, Christine H. Chung, Rebecca Redman, Alexandre Coutte, Sebastien Salas, Cliona Grant, Sergio de Azevedo, Denis Soulieres, Aaron R. Hansen, Li Wei, Tariq Aziz Khan, Karen Miller-Moslin, Mustimbo Roberts, Robert Haddad
Summary: The clinical benefit of first-line nivolumab plus ipilimumab was evaluated in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study found that nivolumab plus ipilimumab did not improve clinical outcomes compared to nivolumab alone in these patients. Further research is needed to identify subpopulations of R/M SCCHN patients who would benefit from nivolumab plus ipilimumab therapy.
Article
Oncology
Susan Lalondrelle, Jen Lee, Rosalind J. Cutts, Isaac Garcia Murillas, Nik Matthews, Nicholas Turner, Kevin Harrington, Katherine Vroobel, Emily Moretti, Shreerang A. Bhide
Summary: Human papilloma virus (HPV) is a major cause of cervical cancer, and there is currently no reliable method to predict early relapse. We have developed a blood test that can accurately detect HPV-DNA fragments in the blood, which can be used to assess treatment response and monitor relapse.
Article
Oncology
P. Martin, Z. Tsourti, J. Ribeiro, L. Castelo-Branco, E. de Azambuja, S. Gennatas, J. Rogado, M. Sekacheva, S. Susnjal, D. Vinal, R. Lee, S. Khallaf, G. Dimopoulou, S. Pradervand, J. Whisenant, T. K. Choueiri, D. Arnold, K. Harrington, K. Punie, J. Oliveira, O. Michielin, U. Dafni, S. Peters, G. Pentheroudakis, E. Romano
Summary: This paragraph summarizes the results of a study analyzing COVID-19 patients, which found that factors such as symptomatic patients, males, older age, ethnicity other than Asian/Caucasian, Eastern Cooperative Oncology Group performance status >2, body mass index <25, hematological malignancy, progressive disease versus no evident disease, and advanced cancer stage significantly affect COVID-19 outcomes.
Article
Oncology
Karan Patel, Massimiliano Manzo, Brindley Hapuarachi, Samuel Rack, Philip Jermann, Laura Feeney, Emily Heathcote, Guy Betts, Jon C. Aster, Maximilien Murone, Maria Bobadilla, Rajwinder Lehal, Florian D. Vogl, Kevin Harrington, Robert Metcalf
Review
Oncology
Rita Simoes, Yolanda Augustin, Sarah Gulliford, Hakim-Moulay Dehbi, Peter Hoskin, Elizabeth Miles, Kevin Harrington, Aisha B. Miah
Summary: This systematic review summarizes the incidence of acute and late toxicities in soft tissue sarcoma of the extremities (STSE) patients undergoing radiotherapy. It also discusses the limitations in guidance on normal tissue and dose-volume parameters for optimizing radiotherapy plans in STSE.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Oncology
Nikhil Manish Patel, Georgios Geropoulos, Pranav Harshad Patel, Ricky Harminder Bhogal, Kevin Joseph Harrington, Aran Singanayagam, Sacheen Kumar
Summary: Diagnosis of oesophago-gastric cancer is challenging, but non-invasive risk stratification can identify susceptible patients with pre-malignant or benign diseases. Early oesophago-gastric cancer can be treated sooner following diagnostic confirmation through endoscopic biopsy. Mucins, transmembrane glycoproteins implicated in oesophago-gastric cancer, have the potential to be used as biomarkers for malignant transformation. This systematic review examines the role of mucins in the diagnosis of oesophago-gastric cancer.
Meeting Abstract
Oncology
Georgia M. Beasley, Ari M. VanderWalde, Tawnya L. Bowles, Joseph J. Sacco, Jiaxin Niu, Katy K. Tsai, Jason A. Chesney, Bartosz Chmielowski, Adel Samson, Terence Duane Rhodes, Gino K. In, Anna C. Pavlick, Trisha M. Wise-Draper, Miguel F. Sanmamed, Jeannie Hou, Mark R. Middleton, Kevin Harrington, Celeste Lebbe, Judith Michels, Mohammed M. Milhem
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Dentistry, Oral Surgery & Medicine
Ashwin Algudkar, Kevin Harrington, Cyrus Kerawala, Izhar Bagwan, Derfel Ap Dafydd
Summary: This study summarizes the imaging recommendations and characteristics of head and neck mucosal melanoma (HNMM), and provides revised guidelines to guide the investigation and management of this rare and aggressive cancer.
ORAL AND MAXILLOFACIAL SURGERY-HEIDELBERG
(2023)
Article
Oncology
K. J. Harrington, E. E. W. Cohen, D. Soulieres, J. Dinis, L. Licitra, M. -j. Ahn, A. Soria, J. -p. Machiels, N. Mach, R. Mehra, B. Burtness, R. F. Swaby, J. Lin, J. Ge, N. Lerman, C. Le Tourneau
Summary: Through a study on patients with HNSCC, it was found that pembrolizumab provided longer overall survival and durable responses in all subgroups of recurrence patterns, regardless of previous treatment.